Overall, the cytokine profiles indicate that the functional quality of the tumor antigen-specific T cell response, in addition to the magnitude of the tumor-specific T cell response, is augmented even further by the combination of active immunotherapy plus CTLA-4 checkpoint blockade. Here, CTLA4 is linked to neoplasm.